Vivasure Medical, a Galway, Ireland-based company focused on absorbable technology for percutaneous vessel closure, received a €30m strategic investment from Haemonetics Corporation (NYSE: HAE) as part of its previously disclosed Series D financing.
Haemonetics joined Fountain Healthcare Partners, Orchestra BioMed Holdings, LSP Health Economics Fund, Panakès Partners, Evonik Venture Capital, Enterprise Ireland, and European Investment Bank.
The company intends to use the clinical study results to support an FDA pre-market approval submission as well as multinational commercial launch of the PerQseal system for large hole vessel closure.
Led by CEO Andrew Glass, Vivasure is focused on the development of advanced polymer implants and delivery systems, primarily focused on minimally invasive vessel closure in cardiology, interventional radiology and vascular surgery. PerQseal is designed to be the first sutureless, fully absorbable synthetic implant for large-bore vessel punctures. Its low profile patch can be placed from inside the vessel and is intended to make deployment simpler and more controlled than conventional closure techniques. Clinical studies to date have shown a low complication rate and high technical success.
The company operates a fully integrated R&D and ISO 13485 certified manufacturing facility and is backed by leading international medtech investors.
Vivasure Medical has also received support from Enterprise Ireland and the European Investment Bank.
FinSMEs
13/03/2023